TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01342224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tadalafil and vaccination
Description: Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
Study: NCT01641393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 25,000 Units
Description: EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 25,000 Units
Description: EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kreon 25,000 Units
Description: Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kreon 25,000 Units
Description: Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
Study: NCT02685644

Intervention type: PROCEDURE
Intervention: Laparoscopic removal of cysts
Description: Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
Study: NCT02448251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010MA
Description: Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010MA
Description: Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
Study: NCT02604290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping method
Description: The tape is applied depending on the physical examination:~* Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~* Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~* Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio Taping sham
Description: The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
Study: NCT04123067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Description: 45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
Study: NCT04995679

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implant of metaphyseal sleeves in Total knee arthroplasty
Description: Implant of metaphyseal sleeves in Primary and revision TKA
Study: NCT03144414

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: Laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: Laparoscopic hysterectomy
Study: NCT02633137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: * Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high-dose cytarabine (HIDAC)
Study: NCT03741101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: treatment
Study: NCT01843374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is to be administered as an IV solution, followed by observation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is to be administered as an IV solution, followed by observation.
Study: NCT02084459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive counselling (GSD)
Description: GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
Study: NCT02954354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: 2 to4 X 20-mg tablets taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: 2 to4 X 20-mg tablets taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Baloxavir Marboxil
Description: 2 to4 X 20-mg tablets taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Baloxavir Marboxil
Description: 2 to4 X 20-mg tablets taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Baloxavir Marboxil
Description: 2 to4 X 20-mg tablets taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: 75 mg capsules taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Oseltamivir
Description: Placebo capsules matching oseltamivir 75 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Oseltamivir
Description: Placebo capsules matching oseltamivir 75 mg capsules
Study: NCT03683147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation-Based Stress Reduction Program
Description: Participate in 6-week online program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation-Based Stress Reduction Program
Description: Participate in 6-week online program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03697109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant is supplied as 100 mg capsules for oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant is supplied as 100 mg capsules for oral dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to study drug
Study: NCT04252742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 140 mg, 2 consecutive injections of 70 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 consecutive injections
Study: NCT03611348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~* To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
Study: NCT01533493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS-Methylphenidate
Description: OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OROS-Methylphenidate
Description: OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
Study: NCT06256133

Intervention type: PROCEDURE
Intervention: Enhanced Recovery After Surgery protocol
Description: Preoperative oral carbohydrate loading, Ultrasound-assisted thoracic epidural catheter placement, Intraoperative individualized goal-directed fluid therapy, Active warming techniques, The inspired fractional concentration of oxygen was maintained, Multimodal postoperative nausea and vomiting (PONV) prevention strategies, Anesthesia was maintained using a target-controlled infusion (TCI) of propofol and remifentanil, Scheduled administration of an intravenous (IV) or oral nonsteroidal anti-inflammatory drug (NSAID) (50 mg of dexketoprofen)
Study: NCT03230773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator model
Description: Comparison of the performance of different public access defibrillators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator model
Description: Comparison of the performance of different public access defibrillators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator model
Description: Comparison of the performance of different public access defibrillators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator model
Description: Comparison of the performance of different public access defibrillators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator model
Description: Comparison of the performance of different public access defibrillators

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillator model
Description: Comparison of the performance of different public access defibrillators
Study: NCT03905330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maralixibat
Description: Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to maralixibat orally twice daily for 26 weeks.
Study: NCT02433743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF)
Description: HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
Study: NCT03151681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Pill
Description: 1mg/kg of propranolol 60 minutes prior to memory reactivation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Pill
Description: 1mg/kg of propranolol 60 minutes prior to memory reactivation
Study: NCT02058537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol
Description: Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
Study: NCT02729766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced hypotonic hyponatremia - SIAD model

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Induced hypotonic hyponatremia - SIAD model

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25mg Tbl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo P-Tablet
Study: NCT00717834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant
Description: Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
Study: NCT03766867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine infusion 25 mg
Description: 1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine tablets 10 mg/day
Description: 10 mg, tablets, oral administration once daily
Study: NCT02063828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A - Device guided breathing low dose
Description: Group A: 15 minutes once a day, 5 days a week for 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B - Device guided breathing high dose
Description: Group B - 15 minutes twice a day, 5 days a week for 12 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Group C - Usual Breathing Control Group
Description: Group C - 15 minutes per day, 5 days a week for 12 weeks.
Study: NCT04414449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICT-enabled Social-emotional Learning
Description: ICT-enabled Social-emotional Learning
Study: NCT00901628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: 750mg intraoperative periarticular injection
Study: NCT01167920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Hypertension Clinic
Description: In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
Study: NCT02642627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bellafill
Study: NCT01693068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
Study: NCT02029079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: E+
Description: 300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
Study: NCT01687257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00969501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUFLEXXA
Description: 2.5 mL of EUFLEXXA (per injection) x 3 injections
Study: NCT00736645

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenomethionine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: finasteride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: finasteride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT00760149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifampicin in higher doses
Description: Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin in higher doses
Description: Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin in higher doses
Description: Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)